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Introduction: We describe clinical, pathologic, and molecular char-
acteristics of never-smoker patients with small-cell lung cancers 
(SCLCs).
Methods: We identified cases of SCLCs evaluated at our institution 
from 2005 to 2012. We collected smoking history, demographic, 
treatment, and survival data. EGFR, KRAS, PIK3CA, ALK testing, 
RB protein expression, and next generation sequencing were per-
formed on available samples.
Results: Two percent (23 of 1040) of patients with SCLCs were 
never-smokers. Eighty-three percent (19 of 23) had de novo SCLCs, 
whereas 17% had SCLC transformation as acquired resistance to 
erlotinib after treatment for EGFR-mutant lung carcinomas. Median 
survival from SCLC diagnosis was 23 months. Of de novo SCLCs, 
ALK rearrangement, KRAS mutations, EGFR mutations, and RB loss 
were identified in zero of five, zero of eight, two of eight, and six of 
seven, respectively. Two de novo samples underwent next generation 
sequencing. One had mutations in p53 and RB1 with amplification in 
TERT, and a second had mutations in CBL and GNAS with amplifica-
tion in MYCL1.
Conclusions: Two percent of patients with SCLCs are  never-smokers. 
Although transformation to SCLC can rarely occur in acquired resis-
tance to erlotinib, 83% of never-smokers with SCLCs had de novo 
SCLC. RB loss was noted in 86% of cases. Multiplexed genotyping 
can be performed on tissues to identify potentially actionable onco-
genic drivers.
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Although tobacco smoking remains the most important risk factor for the development of small-cell lung cancer 
(SCLC), an epidemiologic study reported that 3% of patients 
with SCLCs are never-smokers.1 Several reports describe 
the rare, but well-documented, phenomenon of transforma-
tion to SCLC as a mechanism of acquired resistance (AR) 
to epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors (TKIs) in 4 to 14% of patients initially treated for 
 EGFR-mutant lung adenocarcinomas, including in some 
patients who are never-smokers.2–5
Scant literature exists describing de novo SCLCs among 
patients who are never-smokers. We report on 23 patients with 
SCLCs who classify themselves as never-smokers.
MATERIALS AND METHODS
Patient Identification and Smoking 
History Documentation
We performed a retrospective review of 1040 SCLC 
patients evaluated at Memorial Sloan-Kettering Cancer Center 
between 2005 and 2012. Patients with lung cancers assessed 
at Memorial Sloan-Kettering Cancer Center complete a pro-
spective, self-administered smoking questionnaire at the ini-
tial visit. Never-smokers are defined as those patients who 
report having smoked ≤100 cigarettes in their lifetime.
Pathologic Review of SCLC
The diagnosis of SCLC was confirmed through histo-
logic and immunohistochemical (IHC) testing (chromogranin, 
synaptophysin, CD56, and MIB1) by a thoracic pathologist.
KRAS, EGFR, ALK, and RB Testing
Patients with sufficient tissue underwent testing for 
EGFR and KRAS mutations and ALK rearrangements. EGFR 
mutations (exon 19 deletions and exon 21 L858R amino acid 
substitutions) were identified by mutation-specific PCR-based 
methods.6–8 KRAS codons 12 and 13 mutation identification 
was performed by both mass spectrometry (Sequenom, Inc., 
San Diego, CA)-based genotyping and direct sequencing. 
ALK rearrangements were tested using either fluorescence 
in situ hybridization (dual-color break-apart ALK probe, 
Abbott Molecular, Abbott Park, IL) or IHC (ALK-01 Ventana 
790–2918). RB expression was analyzed using IHC (clone 
1F8, Leica Biosystems, Buffalo Grove, IL).
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Comprehensive, Integrated Mutation 
Analysis of Actionable Cancer Genes Using 
Next Generation Sequencing (NGS)
DNA was extracted from biopsied tissue and cytology 
specimens (and patient-matched normal tissue) using Qiagen 
nucleic acid extraction kits. Using our MSK-IMPACT (inte-
grated mutation profiling of actionable cancer targets) assay, 
bar-coded sequence libraries were prepared (Illumina TruSeq), 
and exon capture was performed on bar-coded pools by hybrid-
ization (Agilent SureSelect Target Enrichment) using custom 
oligonucleotides to capture all exons and select introns of 279 
cancer genes. DNA was sequenced on an Illumina HiSeq 2000 
to maximize sensitivity for detecting mutations. This strategy 
enables the identification of mutations, indels, and copy num-
ber alterations involving these 279 genes.
RESULTS
Incidence
Two percent of patients (23 of 1040) with SCLCs were 
never-smokers. Among never-smokers with SCLCs, 83% (19 
of 23) had de novo SCLCs, and 17% (4 of 23) of patients 
had small-cell transformation as a mechanism of AR to EGFR 
TKIs in EGFR-mutant lung adenocarcinoma. Baseline char-
acteristics are listed in Table 1. Clinical and pathologic char-
acteristics of each patient are listed in Table 2.
de novo SCLC
Pathologic characteristics
Pathologic rereview confirmed the following: 15 pure 
SCLC; one mixed SCLC and large cell neuroendocrine 
carcinoma; one SCLC and spindle and giant cell carcinoma 
(Figs 1A, 1B); and two mixed SCLC and adenocarcinoma.
Clinical characteristics
Of 19 patients with de novo SCLCs, 5 were either lost to 
follow-up or had inadequate information available regarding 
treatment course and response. Of the 14 cases with available 
treatment history, all received first-line etoposide/platinum 
doublets. Fifty-seven percent of these patients (8 of 14) had a 
response to chemotherapy that lasted ≥3 months from comple-
tion of first-line therapy. Median time to progression was 11 
months (95% CI: 5–13 months). Median overall survival (OS) 
from the time of SCLC diagnosis was 23 months (95% CI: 
10–27 months).
EGFR, KRAS, ALK, and RB Testing
Of the 19 de novo SCLC cases, 8 underwent testing 
for EGFR Exon 19 deletion and Exon 21 L858R mutation. 
An EGFR L858R mutation was found in one patient, whose 
tumor contained SCLC and adenocarcinoma components. 
This patient initially received erlotinib, carboplatin, and eto-
poside, with progression of disease within three months of 
completing chemotherapy. Although he continued erlotinib 
throughout his subsequent chemotherapeutic regimens, 
his disease rapidly progressed. The tumor of one patient 
with pure SCLC harbored an EGFR Exon 19 deletion and 
PIK3CA E545K mutation. This patient had progressive dis-
ease after four cycles of etoposide/platinum. He was then 
initiated on erlotinib, with progression of disease after just 
4 weeks of therapy.
There were no KRAS mutations or ALK rearrange-
ments identified in the cases tested for these alterations. Six 
of seven cases tested for RB expression demonstrated RB loss 
(Table 3).
Acquired Resistance SCLC
Pathologic characteristics
Of the four patients with SCLC as a mechanism of 
AR to EGFR TKIs, two had pure SCLC, one had mixed his-
tology of SCLC and adenocarcinoma, and one had SCLC, 
adenocarcinoma, and large cell neuroendocrine carcinoma 
components.
Clinical characteristics
All four patients were women (median 48 years; range 
40–75 years) at the diagnosis of SCLC transformation from 
EGFR-mutant lung adenocarcinoma. Once the diagnosis of 
SCLC was made, two patients received platinum/etoposide. 
One of these patients underwent local therapy with surgi-
cal resection of a lung nodule that demonstrated recurrent 
growth, although all other sites of disease had resolved.9 
Pathology review of this specimen with acquired resistance 
demonstrated SCLC, adenocarcinoma, and large cell neu-
roendocrine carcinoma components. After receiving six 
cycles of adjuvant carboplatin, etoposide, and erlotinib 
therapy, this patient had a nine-month, disease-free inter-
val after treatment. The two patients who did not receive 
platinum/etoposide therapy had varied treatments and 
clinical courses.
TABLE 1.  Clinical Characteristics of Patients with Small-Cell 
Lung Cancer (SCLC) Who Are Never-Smokers
SCLC as  
Acquired  
Resistance  
(n = 4)‡
de novo SCLC 
(n = 19)
Sex
  Male 0 9
  Female 4 10
Median age at diagnosis (range) 48 (42–75)* 65 (35–94)
Race
  White 2 13
  Black 0 3
  Asian 2 3
Stage at diagnosis
  Limited 0 5
  Extensive 4 14
Brain metastases at presentation
  Yes 2 4
  No 2 15
‡All four of these patients had been treated with erlotinib.
*For patients with SCLC transformation as a mechanism of acquired resistance to 
EGFR TKIs, median age at diagnosis is the age at which SCLC transformation was 
diagnosed.
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EGFR, KRAS, ALK, and RB testing
The patients with SCLC as a mechanism of AR to EGFR 
TKI had persistence of the original EGFR mutation in their 
tumors confirmed on biopsy taken at the time of resistance. 
Of three cases also tested for EGFR Exon 20 T790M mutation 
at the time of AR, two had the second-site EGFR Exon 20 
T790M mutation, in addition to SCLC. Insufficient tissue was 
available for RB testing in these samples.
Comprehensive mutation analysis of actionable cancer 
genes using NGS
Two patients had adequate tissue available for NGS. 
In one patient, analysis revealed five mutations in four 
genes: PHOX2B, NOTCH1, RB1, and TP53. In addition, 
amplification was seen in TERT. NGS analysis of the second 
patient’s sample revealed two mutations in the two genes 
CBL and GNAS, with amplification seen in MYCL1. Neither 
patients’ samples had smoking-associated G -->T transver-
sions (Table 4).
DISCUSSION
Two percent of SCLCs at our institution occurred in 
never-smokers. This represents the largest cohort of clinically 
and pathologically described never-smokers with SCLC. Of 
these diagnoses, 83% were made de novo.
Pathologic review of these SCLC cases confirmed the 
diagnosis. IHC for RB loss was performed on seven samples, 
and six of these revealed RB loss, consistent with lung can-
cer of SCLC lineage.10 Of eight patients with de novo SCLCs 
TABLE 2.  Clinical and Pathologic Characteristics of Small-Cell Lung Cancers (SCLC) Among Never-Smokers
Patient Number Sex
de novo or Acquired 
Resistance Stage Pathology Mutations Identified
1† M de novo Extensive SCLC
2 F de novo Limited SCLC/spindle cell
3† F de novo Limited SCLC
4 F de novo Limited SCLC EGFR WT/KRAS WT
5 F de novo Extensive SCLC EGFR WT/KRAS WT
6 F de novo Extensive SCLC EGFR WT/KRAS WT
7 M de novo Extensive SCLC EGFR WT/KRAS WT
8 F de novo Extensive SCLC EGFR WT/KRAS WT
9 M de novo Extensive SCLC ADC EGFR L858R/KRAS WT
10 M de novo Limited SCLC/ADC
11 F de novo Extensive SCLC/large cell neuroendocrine carcinoma
12 M de novo Extensive SCLC
13 M de novo Extensive SCLC EGFR Exon 19 del*
14 F AR Extensive SCLC EGFR Exon 19 del
15 F AR Extensive SCLC/ADC/neuroendocrine carcinoma EGFR Exon 19 del
16 F AR Extensive SCLC/ADC EGFR Exon 19 del
17 M de novo Extensive SCLC
18 F de novo Limited SCLC
19 F de novo Extensive SCLC
20 F de novo Extensive SCLC
21 M de novo Extensive SCLC
22 F AR Extensive SCLC EGFR Exon 19 del
23 M de novo Extensive SCLC EGFR WT/KRAS WT
*This patient’s tumor also harbored a PIK3CA E545K mutation.
† Please see Table 4 for next generation sequencing results.
M, male; F, female; AR, acquired resistance; ADC, adenocarcinoma.
FIGURE 1. A, Mixed small-cell and 
giant and spindle cell carcinoma 
at left with a higher power image 
of giant cell on the right using 
hematoxylin and eosin staining. (B) 
Neuroendocrine staining of mixed 
small-cell and giant and spindle cell 
carcinoma with chromogranin stain. 
Note lack of stain in the giant cell 
areas.
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tested for EGFR mutations, one patient with mixed SCLC 
and adenocarcinoma had an EGFR L858R mutation, and a 
second patient with pure SCLC had a tumor with mutations 
in both EGFR (exon 19 deletion) and PIK3CA (E545K). 
Unlike patients with EGFR-mutant lung adenocarcinomas 
and many patients with SCLC, these patients suffered rapid 
progression of disease that did not respond to therapy with 
EGFR TKIs or platinum/etoposide. Median OS in SCLC 
never-smokers was 23 months, which is longer than gener-
ally seen in SCLC.11
Of the four cases with SCLC as a mechanism of AR 
to EGFR TKIs in EGFR-mutant lung adenocarcinoma, two 
received cisplatin and etoposide. One patient had a partial 
response with a disease-free survival of 9 months, and the 
other did not respond. This small group represents a hetero-
geneous population in which the disease biology and clinical 
course can mirror both EGFR-mutant lung adenocarcinoma 
and SCLC.
The presence of EGFR mutations in tumors from 
patients with SCLCs remains an area of controversy. 
Although an EGFR mutation in the setting of a mixed diag-
nosis of SCLC and adenocarcinoma can be seen with the 
EGFR mutation arising from the adenocarcinoma compo-
nent, the etiology of the EGFR mutations in a single biopsy 
of SCLC is unclear. Prior work from our group has dem-
onstrated that EGFR mutations do not exist in pure SCLC 
or squamous cell lung cancer.12,13 One interpretation is that 
this finding of pure SCLC represents sampling error in the 
setting of tumor heterogeneity rather than two oncogenic 
mechanisms in a single cell.
Further molecular analysis using NGS of exons of 279 
cancer genes revealed mutations in TP53, Notch, and RB1, 
consistent with prior reports regarding the molecular basis of 
SCLC.14–16 Interestingly, no smoking-associated G -->T trans-
versions were observed in the two samples tested.
Our analysis has several limitations. This is a retro-
spective study. Given the rarity of patients with SCLCs 
who are never-smokers, prospective identification and 
analysis of these patients are difficult. The available tissue 
for molecular analysis was limited, and molecular testing 
could only be performed on a minority of the patients iden-
tified. The patients in this series were identified as never-
smokers based on  self-report and direct questioning by the 
medical staff.
Patients with SCLCs who are never-smokers represent 
a clinically and pathologically distinct population because 
they bear little similarity to non-SCLCs among never-smok-
ers. Their molecular characteristics are unique compared 
with never-smoker patients with adenocarcinomas. The 
transformation of EGFR-mutant lung adenocarcinomas to a 
SCLC phenotype coincident with the emergence of EGFR 
TKI AR is an area of much interest and research relative to 
its rarity. This study further supports the need for compre-
hensive, multiplexed genotyping to improve our ability to 
provide optimal care and facilitate research in these unique 
populations.
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